bioMérieux S.A. (LON:0RUG)

Arcadium Lithium Statistics

Total Valuation

bioMérieux has a market cap or net worth of GBP 12.79 billion. The enterprise value is 12.83 billion.

Market Cap	12.79B
Enterprise Value	12.83B

Important Dates

The next estimated earnings date is Thursday, September 4, 2025.

Earnings Date	Sep 4, 2025
Ex-Dividend Date	Jun 9, 2025

Share Statistics

Current Share Class	117.93M
Shares Outstanding	n/a
Shares Change (YoY)	-0.06%
Shares Change (QoQ)	+0.24%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	44.60M

Valuation Ratios

The trailing PE ratio is 35.79 and the forward PE ratio is 27.56.

PE Ratio	35.79
Forward PE	27.56
PS Ratio	3.89
PB Ratio	3.67
P/TBV Ratio	5.19
P/FCF Ratio	48.11
P/OCF Ratio	23.18
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.07, with an EV/FCF ratio of 48.26.

EV / Earnings	35.90
EV / Sales	3.72
EV / EBITDA	15.07
EV / EBIT	23.20
EV / FCF	48.26

Financial Position

The company has a current ratio of 2.20, with a Debt / Equity ratio of 0.12.

Current Ratio	2.20
Quick Ratio	1.22
Debt / Equity	0.12
Debt / EBITDA	0.50
Debt / FCF	1.53
Interest Coverage	39.87

Financial Efficiency

Return on equity (ROE) is 10.68% and return on invested capital (ROIC) is 8.89%.

Return on Equity (ROE)	10.68%
Return on Assets (ROA)	7.23%
Return on Invested Capital (ROIC)	8.89%
Return on Capital Employed (ROCE)	13.76%
Revenue Per Employee	227,753
Profits Per Employee	24,733
Employee Count	14,754
Asset Turnover	0.72
Inventory Turnover	1.81

Taxes

In the past 12 months, bioMérieux has paid 127.60 million in taxes.

Income Tax	127.60M
Effective Tax Rate	26.63%

Stock Price Statistics

The stock price has increased by +28.67% in the last 52 weeks. The beta is 0.48, so bioMérieux's price volatility has been lower than the market average.

Beta (5Y)	0.48
52-Week Price Change	+28.67%
50-Day Moving Average	120.72
200-Day Moving Average	112.85
Relative Strength Index (RSI)	60.14
Average Volume (20 Days)	33,271

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, bioMérieux had revenue of GBP 3.29 billion and earned 357.42 million in profits. Earnings per share was 3.01.

Revenue	3.29B
Gross Profit	1.83B
Operating Income	527.52M
Pretax Income	479.15M
Net Income	357.42M
EBITDA	784.13M
EBIT	527.52M
Earnings Per Share (EPS)	3.01

Balance Sheet

The company has 371.97 million in cash and 405.79 million in debt, giving a net cash position of -33.82 million.

Cash & Cash Equivalents	371.97M
Total Debt	405.79M
Net Cash	-33.82M
Net Cash Per Share	n/a
Equity (Book Value)	3.48B
Book Value Per Share	29.49
Working Capital	1.13B

Cash Flow

In the last 12 months, operating cash flow was 551.84 million and capital expenditures -285.97 million, giving a free cash flow of 265.87 million.

Operating Cash Flow	551.84M
Capital Expenditures	-285.97M
Free Cash Flow	265.87M
FCF Per Share	n/a

Margins

Gross margin is 55.66%, with operating and profit margins of 16.03% and 10.86%.

Gross Margin	55.66%
Operating Margin	16.03%
Pretax Margin	14.56%
Profit Margin	10.86%
EBITDA Margin	23.82%
EBIT Margin	16.03%
FCF Margin	8.08%

Dividends & Yields

This stock pays an annual dividend of 0.76, which amounts to a dividend yield of 0.61%.

Dividend Per Share	0.76
Dividend Yield	0.61%
Dividend Growth (YoY)	4.97%
Years of Dividend Growth	n/a
Payout Ratio	25.18%
Buyback Yield	0.06%
Shareholder Yield	0.67%
Earnings Yield	2.79%
FCF Yield	2.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 20, 2017. It was a forward split with a ratio of 3.

Last Split Date	Sep 20, 2017
Split Type	Forward
Split Ratio	3

Scores

bioMérieux has an Altman Z-Score of 5.99 and a Piotroski F-Score of 7.

Altman Z-Score	5.99
Piotroski F-Score	7